Antibodies directed against programmed death-1 (PD-1)
US11155624B2 · kind B2 · utility
2Cited by
28References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 1, 2017 |
| Grant date | Oct 26, 2021 |
| Priority date | — |
| Expiry date | Jun 5, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive to PD-1 inhibition, such as cancer or an infectious disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.